FDA’s refusal to make its new policy providing five years of market exclusivity for certain fixed-dose combination drugs retroactive could push firms left out of the new regime to sue the agency.
The agency issued final guidance on new chemical entity exclusivity determinations for certain fixed combinations on Oct. 10....